134 related articles for article (PubMed ID: 21767907)
1. Re: Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur urol 2011;60:279-90.
Braillon A
Eur Urol; 2011 Oct; 60(4):e33. PubMed ID: 21767907
[No Abstract] [Full Text] [Related]
2. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
3. Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
Drewa T; Chlosta P
Eur Urol; 2010 Feb; 57(2):e18-9; author reply e20. PubMed ID: 19853990
[No Abstract] [Full Text] [Related]
4. Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Shen Y; Ye D
Eur Urol; 2012 Feb; 61(2):e3; author reply e4-5. PubMed ID: 21824719
[No Abstract] [Full Text] [Related]
5. Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
Bensimon L; Suissa S; Azoulay L
Eur Urol; 2013 Aug; 64(2):e28. PubMed ID: 23619391
[No Abstract] [Full Text] [Related]
6. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
7. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
Friedman AE
Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
[No Abstract] [Full Text] [Related]
8. Re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56:594-605.
Friedman AE
Eur Urol; 2010 Feb; 57(2):e16; author reply e17. PubMed ID: 19914774
[No Abstract] [Full Text] [Related]
9. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.
Galsky MD; Oh WK
Lancet Oncol; 2013 Jul; 14(8):681-2. PubMed ID: 23742876
[No Abstract] [Full Text] [Related]
10. Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
von Eyben FE; Virgolini I; Roviello G
Eur Urol; 2018 Feb; 73(2):e31. PubMed ID: 28869068
[No Abstract] [Full Text] [Related]
11. Novel chemotherapies in development for management of castration-resistant prostate cancer.
Tewari AK; George DJ
Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
[TBL] [Abstract][Full Text] [Related]
12. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
13. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
Gillessen S; de Bono JS; Sartor O; Omlin AG
Eur Urol; 2018 Feb; 73(2):e32-e33. PubMed ID: 28869069
[No Abstract] [Full Text] [Related]
14. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
Spratt DE; Zhang Z; Zelefsky MJ
Eur Urol; 2013 Aug; 64(2):e29-30. PubMed ID: 23619389
[No Abstract] [Full Text] [Related]
15. Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012.
von Eyben FE; Bauman G; Soydal C; Paganelli G
Eur Urol; 2020 Nov; 78(5):e201-e202. PubMed ID: 32222292
[No Abstract] [Full Text] [Related]
16. Castration-resistant prostate cancer: targeted therapies.
Leo S; Accettura C; Lorusso V
Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
18. The role of IMiDs alone or in combination in prostate cancer.
Nabhan C; Petrylak DP
Clin Genitourin Cancer; 2012 Sep; 10(3):141-6. PubMed ID: 22608152
[TBL] [Abstract][Full Text] [Related]
19. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Rexer H
Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
[No Abstract] [Full Text] [Related]
20. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
Garcia JA; Rini BI
Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
